NASHPUBLICATIONS 06/2024 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH EASL International Liver Congress charlie maddox Love0
NASHPUBLICATIONS 06/2024 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice EASL International Liver Congress charlie maddox Love0
NASHPUBLICATIONS 06/2024 Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis EASL International Liver Congress charlie maddox Love0
NASH 11/2023 Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model 7th Obesity and NASH Drug Development Summit Graviton Love0
NASHPUBLICATIONS 11/2023 Artificial Intelligence Based Digital Pathology Reveals Fatty Acid Synthase (FASN) Inhibitor Alone or in Combination with Semaglutide Improves Fibrosis in Diet-Induced Obese Mice with Biopsy-Confirmed NASH and Fibrosis AASLD The Liver Meeting Graviton Love0
NASHPUBLICATIONS 11/2023 Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity AASLD The Liver Meeting Graviton Love0
NASH 06/2023 Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial EASL International Liver Congress Lehi Vidigal Love0
NASH 01/2023 Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies NASH-TAG Graviton Love0
NASH 01/2023 Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients NASH-TAG Graviton Love0
NASH 11/2022 Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH AASLD The Liver Meeting Graviton Love0